A phase II study evaluating efficacy of zoledronic acid in prevention of aromatase inhibitor (AI)-associated musculoskeletal symptoms: The ZAP trial.
Cesar Augusto Santa-Maria
No relevant relationships to disclose
Aditya Bardia
No relevant relationships to disclose
Amanda Blackford
No relevant relationships to disclose
Roisin M. Connolly
Research Funding - Genentech; Novartis; Puma
John H. Fetting
No relevant relationships to disclose
Stacie Jeter
No relevant relationships to disclose
Robert Stephen Miller
No relevant relationships to disclose
Anne T Nguyen
No relevant relationships to disclose
Katie Quinlan
No relevant relationships to disclose
Shannon Slater
No relevant relationships to disclose
Claire Frances Snyder
Stock Ownership - Express Scripts; Immunomedics; Merck; Oncolytics Biotech
Antonio C. Wolff
No relevant relationships to disclose
Jane Zorzi
No relevant relationships to disclose
N. Lynn Henry
Research Funding - AstraZeneca
Vered Stearns
Research Funding - Novartis; Pfizer